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Identification of nitric oxide as the molecule responsible for endothelial dependant
vasodilatation has led to an explosion of interest in endothelial function. Oxidative
stress has been identified as an important factor in the development of tolerance to
organic nitrates. This review examines the evidence supporting this recently devel-
oped theory and how mechanisms of nitrate tolerance may link with the wider
picture of primary nitric oxide resistance.
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Introduction
 
Nitrates have been used in clinical practice as anti-anginal
treatment for over a century [1]. However, the link
between nitric oxide and endothelial function has been
demonstrated more recently. In 1980, Furchgott 
 
et al.
 
published data describing the importance of the endot-
helial layer in mediating acetylcholine-induced vasodila-
tation of rabbit aortic rings [2]. The term endothelial
derived relaxing factor (EDRF) was used to define this
endothelial agent which was easily lost if the endothe-
lium was inadvertently damaged. Soon after this obser-
vation, EDRF was identified as nitric oxide (NO) [3]
and the pathway responsible for its synthesis from 
 
L
 
-
arginine was described [4]. With this came the important
observation that a closely related analogue of 
 
L
 
-arginine,
L-NMMA (N
 
G
 
-methyl-L-arginine) could competitively
inhibit the pathway. Furchgott’s work, along with that of
Ignarro and Murad, was recognized with the Nobel Prize
for Medicine in 1998.
It is now apparent that NO is important in mediating
other cellular signals. Different isoenzymes of nitric oxide
synthase (NOS) have been identified in neuronal signal-
ling, and as an inducible form, in mediating inflamma-
tion in severe sepsis [4]. NO is also involved in a number
of anti-atherogenic processes, such as suppressing platelet
aggregation and smooth muscle cell proliferation [4].
Endothelial NOS (eNOS) is the key source of nitric
oxide within the vascular endothelium. Constant back-
ground release of nitric oxide by eNOS helps maintain
physiological vascular tone. However, eNOS agonists
such as acetylcholine (Ach) can increase NO levels and
thus are able to modulate vascular tone [4].
 
L-arginine pathway 
 
[Figure 1]
This pathway enables the production of endogenous NO
from the substrate 
 
L
 
-arginine within the endothelial cell.
Situated within the endothelium, NOS converts 
 
L
 
-
arginine to NO and the by-product 
 
L
 
-citrulline. In turn,
NO diffuses from the endothelial cell across to the vas-
cular smooth muscle triggering the formation of cyclic
GMP via soluble guanylate cyclase (GC) causing smooth
muscle relaxation and hence vasodilatation. The pharma-
cological action of NO, generated by NO donors, short-
circuits endothelial NOS by diffusing directly across to
the smooth muscle layer. Hence vasodilatation can be
endothelium 
 
dependent
 
 or 
 
independent
 
.
NOS can be stimulated by a variety of agonists includ-
ing acetylcholine, bradykinin, nebivolol [5] and pravasta-
tin [6]. Of these, acetylcholine is the most commonly
used experimental agent. Recent evidence based on
bovine aortic endothelial cells challenges the generally
accepted mechanism of action of pharmacological
nitrates by demonstrating that NOS can also be stimu-
lated by nitrate donors (such as GTN) [7]. Thus, GTN
may not only act as a nitrate donor but may also be able
to stimulate NOS directly [7]. Cross-tolerance to both
acetylcholine and GTN can be demonstrated experimen-
tally, however, this effect may only be present at lower
doses of acetylcholine [7]. This suggests that the mecha-
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nisms of stimulation may differ between different phar-
macological substances. 
 
In vitro
 
 studies suggest that
tolerance to GTN may be associated with a modulation
of NOS response as reflected by decreased 
 
L
 
-arginine
uptake in tolerant tissue [7].
Furthermore, the recent discovery of a mitochondrial
GTN reductase present in the vascular smooth muscle
adds another dimension to the fate of exogenous nitrates
[8]. 
 
In vitro
 
 studies have demonstrated that this enzyme
(mitochondrial aldehyde dehydrogenase (mt ALDH)) is
able to bioconvert GTN. 
 
In vivo
 
 work with mt ALDH
inhibitors has confirmed that this mechanism results in
elevated cyclic guanosine monophosphate (cGMP) and
vasorelaxation.
 
Nitrate tolerance, NO resistance and 
endothelial dysfunction
 
Nitrate tolerance can be regarded as an extreme example
of nitrate resistance, which exists in a large number of
atherogenic conditions such as hypercholesterolaemia,
type 2 diabetes, smoking and ischaemic heart disease [9].
The endothelial dysfunction present in these conditions
reflects the reduced bioavailability of nitric oxide, which
can be measured experimentally [9] and is thought, in
part, to result from the increased oxidative stress present
in these conditions. Thus, clinically-induced nitrate tol-
erance associated with nitrate-induced renin-angiotensin
activation and oxidant stress may now be regarded as an
extension of the primary pathophysiological phenome-
non of nitric oxide resistance 
 
per se
 
. Hence, the clinical
effects of nitrates may be blunted in the first instance by
an underlying primary NO resistance to give a ‘primary’
nitrate tolerance while a more dramatic, but mechanisti-
cally similar, ‘secondary’ nitrate tolerance develops with
continued use [10]. In clinical terms these two nitrate
tolerance states are very likely to occur frequently within
the same individual. The question of whether secondary
nitrate tolerance superimposed on pre-existing nitric
oxide resistance results in worsening endothelial function
and cardiovascular outcomes remains to be definitively
answered. However, evidence supporting this notion
exists in the form of a Cox multivariate analysis of two
observational coronary secondary prevention studies
which showed an increase in mortality in chronic nitrate-
treated ischaemic heart disease patients following recov-
ery from an acute cardiac event [11]. Also, randomised
controlled trial data exists to show that continuous glyc-
eryl trinitrate (GTN) does worsen endothelial dependant
vasodilatation in both ischaemic heart disease patients
[12] and healthy volunteers [13].
 
Nitrate tolerance
 
In early accounts of nitrate therapy it was known that
prolonged exposure to nitrates resulted in ‘nitrate toler-
ance’, a diminution of the antianginal and vasodilator
response to nitrate treatment. This phenomenon has
restricted the clinical use and effectiveness of nitrates to
the current day. Consequently, there has been much
interest in attempting to understand the mechanisms
involved. Tolerance to nitrates given constantly or in
regular divided doses occurs quickly, i.e. within days [14].
Nitrate tolerance develops 
 
despite
 
 an elevation in the drug
plasma concentration [15] reflecting a decrease in vascular
sensitivity to previously therapeutic levels. This can be
prevented or reduced by inclusion of a nitrate free period
in the dosing schedule. Much debate has centred on
 
Figure 1
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which schedule is best for each nitrate compound. Gen-
erally, twice-daily (oral) doses at 8am and 12 noon, or a
daily patch with 12- h patch-free period seem effective.
A tendency towards nitrate tolerance (as measured by
exercise capacity) develops with steadier 24 h plasma
concentration profiles [16].
Nitrate-tolerant individuals are more susceptible to
enhanced vasoconstriction whenever the plasma nitrate
concentration is allowed to fall – the ‘rebound phenom-
enon’. This is reflected by increased sensitivity to a num-
ber of circulating vasoconstrictor substances such as
catecholamines and angiotensin II (AII) [17]. Clinically
the rebound phenomenon may be more important than
is currently recognized. Evidence suggests that even
intermittent nitrate patch therapy results in increased vas-
oconstrictor sensitivity during the patch-off period [18].
Observational studies of explosives industries workers
confirm an increased relative risk of sudden cardiac death
during off-duty periods [19]. Chronic beta-blocker
administration for stable angina protects against ‘rebound
vasoconstriction’ in patients treated with intermittent
nitrate patches [20]. The mechanism through which beta-
blockers exert their protective effect could include a
dampening down of the effects of increased vasoconstric-
tor levels found in nitrate tolerance [21]. This effect could
be mediated by not only beta adrenoceptor blockade but
also direct inhibition of renin release from the juxtaglom-
erular apparatus, thus preventing the subsequent cascade
of AII release, protein kinase C activation and endothelin
1 mediated sensitization of the vascular smooth muscle
to circulating vasoconstrictors [22].
 
Proposed mechanisms for nitrate tolerance 
 
[Figure 2]
Each stage of the nitric oxide pathway has been exam-
ined with regard to its importance in nitrate tolerance.
Even before the discovery that exogenous and endoge-
nous nitrates shared a common final pathway it was
known that tolerance to one organic nitrate frequently
implied ‘cross tolerance’ to other nitrogenous and non-
nitrogenous substances [23, 24]. In 1973 Needleman [25]
documented the importance of the redox status of thiol
groups in determining nitrate tolerance. For many years
thiol deficiency was thought to be the core mechanism
behind the development of tolerance. Later studies dis-
agreed with this notion, failing to demonstrate any clin-
ical benefit from supplementation with N-acetylcysteine,
a thiol donor [26]. Finally, measurement of arterial &
venous thiol levels in nitrate tolerant/nontolerant rats
individuals showed that thiol groups were not deplete in
nitrate tolerant tissues [27]. In the 1990s attention
focused on neurohormonal activation. Parker 
 
et al.
 
 noted
an increase in circulating catecholamines, stimulation of
the renin-angiotensin system and associated increase in
body weight and lower haematocrit in tolerant subjects
reflecting an increase in intravascular volume [28]. This
physiological response to vasodilatation has been termed
‘pseudotolerance’. The counter-regulatory hormonal
response has been noted to peak at 24 h but disappears
at three days despite a persistent impairment in vascular
response [17]. Another suggested mechanism for toler-
ance is increased breakdown of cGMP by an increase in
phosphodiesterase activity. An inhibitor of phosphodi-
esterase 1 (a1 subclass) has been effective at limiting
tolerance 
 
in vitro
 
 [29]. However, recent attention has
been focused on a novel mechanism that involves
increased free radical activity.
 
The link with oxidative stress
 
An important development in the quest for the key to
tolerance was made in 1995 by Munzel 
 
et al.
 
 [30] who
proposed that nitrate tolerance induced 
 
in vivo
 
 was asso-
 
Figure 2
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ciated with an endothelial dependent production of super-
oxide anion. This notion was supported by work
demonstrating that tolerance (and the production of super-
oxide) could be attenuated by the addition of the enzyme
superoxide dismutase (SOD). Interestingly, as far back as
1986 Gryglewski [31] had noted a link between superoxide
anion and EDRF instability and the protective effect of
SOD. Further supporting evidence for this mechanism
includes the reduced production of superoxide anion
associated with the inclusion of a nitrate free period 
 
in
vivo
 
 [18]. A randomised controlled trial (RCT) of patients
undergoing elective coronary artery bypass grafting, ran-
domised to preoperative intravenous GTN (
 
vs
 
 no intra-
venous GTN), confirms increased superoxide generation
in internal mammary artery samples in the nitrate tolerant
group [32]. This revelation has led many to attempt to
prevent tolerance through the use of antioxidants. Whilst
not all work is confirmatory [33], many have had success
with a variety of antioxidants. Superoxide anion reacts
with NO to form peroxynitrite that is less effective at
stimulating eNOS and also has a shorter half-life [34].
Peroxynitrite can cause nitration of tyrosine residues result-
ing in the formation of 3-nitrotyrosine (a useful marker
of activity) and is elevated in nitrate tolerance [35].
 
Potential sources of superoxide anion
 
Exactly which enzymes are responsible for superoxide
anion generation in the context of nitrate tolerance
remains undecided. 
 
b
 
-nicotinamide adenine dinucleotide
phosphate-dependant membrane-associated oxidase is a
major source of superoxide anion and has been shown
to be activated by AII infusions 
 
in vivo
 
 and also in vascular
smooth muscle cell cultures [36] [37]. Concomitant
administration of losartan and AII in rats has been shown
to normalize superoxide production [36]. Supporting
evidence of NADPH oxidase involvement in the devel-
opment of tolerance comes from work looking at the
protective effect of hydralazine on nitrate tolerance and
subsequent reduction of superoxide anion production via
an NADH oxidase pathway in rabbits [38]. However, a
clinical RCT of heart failure patients and healthy con-
trols has failed to demonstrate any positive effect of
hydralazine (50 mg tds) on nitrate patch-generated
tolerance  [39].  In  situations  with  decreased 
 
L
 
-arginine
substrate, endothelial NOS is known to become uncou-
pled from its production of NO and switch to the pro-
duction of the superoxide anion itself [40]. Although
 
L
 
-arginine is rarely deplete in clinical practice, there is
evidence that 
 
L
 
-arginine supplementation helps to par-
tially prevent tolerance 
 
in vitro
 
 [7]. GTN tolerant endot-
helium also displays reduced L arginine uptake 
 
in vitro
 
[7]. It has been suggested that an apparent deficiency of
substrate may result if eNOS is in some way compart-
mentalized within the endothelial cell [41]. An endoge-
nous NOS inhibitor exists in the form of asymmetric
dimethylarginine (ADMA) which, some groups have
postulated, may be able to modulate endothelial NOS
responses [42]. ADMA, a competitive antagonist of
eNOS, which is equipotent with L-NMMA [42], has
also been shown to increase oxidative stress in human
umbilical endothelial cells [43]. As with other methy-
larginines 
 
L
 
-arginine and L-NMMA, ADMA enters cells
through the y
 
+ transporter and thus can compete for
uptake [42]. Importantly, excess L- arginine is required
to reverse inhibition by L-NMMA or ADMA [44]. In
view of the possible compartmentalization of eNOS in
caveolae within the endothelial cell [44] and the identi-
fication of the y
 
+
 
 transporter on these caveolae [41] it is
possible that the 
 
L
 
-arginine/ADMA ratio is capable of
influencing eNOS activity. Whether this mechanism is
important in iatrogenic nitrate tolerance or just primary
nitric oxide resistance remains to be shown. Outside the
context of nitrate tolerance supplemental 
 
L
 
-arginine has
been shown clinically to restore endothelium dependent
relaxation in patients with heart failure [45].
Certain mechanisms have been postulated for the
observed phenomenon of eNOS ‘uncoupling’. Some
interest surrounds the interrelation of enzymes NADPH
oxidase, protein kinase C (PKC) and eNOS. Long-term
nitroglycerin therapy is also known to activate PKC [22].
PKC in turn has been shown to increase superoxide
anion levels 
 
in vitro
 
 [46]. eNOS is known to be a phos-
phorylation target for PKC [47]. This mechanism is asso-
ciated with NO induced formation of superoxide [48].
Hence the uncoupling of eNOS necessary for the pro-
duction of superoxide anion seems to be dependant on
PKC activation (via PKC activated eNOS phosphoryla-
tion) [49]. Possible candidates for PKC activators include
AII [36] and NO itself.
An alternative mechanism involves tetrahydropbiop-
terin (BH
 
4). Endothelial NOS requires BH
 
4
 
 as a cofactor
to enable the transfer of electrons to 
 
L
 
-arginine and thus
form NO. NOS uncoupling can occur not only in the
presence of reduced 
 
L
 
-arginine but also reduced BH
 
4
[50]. Likewise, BH
 
4
 
 supplementation can reverse this
effect 
 
in vivo
 
 [51]. Furthermore, supplementation with
folic acid (which is involved in BH
 
4
 
 regeneration [52])
has been shown in a clinical, double blind RCT (
 
n
 
 
 
=
 
 18)
to prevent nitrate tolerance in healthy subjects [53]. This
effect appears to be independent of the integral antioxi-
dant effect of folic acid [53].
 
The renin angiotensin system (RAS) and 
nitrate tolerance
 
The RAS is inexorably linked with nitrate tolerance.
RAS activation seems to be involved in both pseudotol-
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erance, the initial baroreflex response which occurs with
all vasodilatory agents and the later true tolerance repre-
sented by resistance to vasodilatation. Many but not all
groups have found angiotensin converting enzyme (ACE)
inhibitors and AII (AII) receptor blockers to have a ben-
eficial effect on nitrate tolerance and this protective effect
seems to be enhanced with higher doses. Animal work
has demonstrated a beneficial effect on tolerance and
prevention of rebound vasoconstriction with high-dose
(1.0 mg kg
 
-
 
1
 
) enalapril 
 
ex vivo
 
 [21]. Similarly, Katz 
 
et al.
 
in a randomised, controlled clinical study with 34 healthy
volunteers, demonstrated that concomitant enalapril
10 mg bd or captopril 25 mg tds completely prevented
tolerance after a 7-day study period [54]. Another clinical
RCT of 26 patients, with a history of chest pain, ran-
domised to seven days captopril 50 mg day
 
-
 
1 or placebo
demonstrated that tolerance to a 48-h infusion of GTN
could be prevented in the captopril group [55]. These
effects have been confirmed in a clinical randomised
controlled trial of 60 patients on IV nitrate therapy due
to unstable angina. In this study addition of captopril
25 mg tds or losartan 50 mg od not only prevented/
reduced the effect of nitrate tolerance but also signifi-
cantly reduced the frequency of recurrent angina and
invasive intervention in the treated group 
 
vs
 
 the control
group who received IV nitrates alone [56]. Conversely,
two studies using a slightly lower dose of captopril (mean
60 mg day
 
-
 
1
 
 for 24 h prior to GTN) in patients with
severe congestive cardiac failure (
 
n
 
 
 
=
 
 21), and benazapril
in healthy volunteers (
 
n
 
 
 
=
 
 20), respectively, have failed to
demonstrate a positive effect [57, 58]. AII receptor block-
ade has been studied in animal models using Losartan
and has been shown to be protective against the devel-
opment of tolerance [59]. This study also demonstrated
an exaggeration of superoxide production (two-fold
increase) in tolerant individuals, which was normalized
in the losartan treated group [59]. A nonselective ET-1
inhibitor (bosentan) had a less potent but similar effect
[59]. Combination therapy of nitrates and ace inhibitors
has also proved useful in clinical practice in the preven-
tion of ventricular remodelling in heart failure patients
[60].
Nitrate tolerance is associated with increased levels of
AII [14]. There is evidence linking AII with enhanced
ET-1 transcription [61] which may partly explain the
enhanced vasoconstrictor response found in nitrate tol-
erance. It has been suggested that enhanced ET-1 activity
acts as an ‘autocrine priming stimulus’ for hypersensitivity
to circulating vasoconstrictors such as catecholamines
[17]. AII may also represent a link between nitrate tol-
erance and superoxide formation. AII is also known to
stimulate NADH/NADPH oxidase in smooth muscle
cell cultures [37] making ace inhibitors and AII blockers
potential ‘antioxidants’ themselves.
 
Antioxidant therapy and the prevention of 
nitrate tolerance
 
Following the development of the superoxide theory in
nitrate tolerance, evidence of the possible beneficial
effects of antioxidant therapy is now emerging.
Classification of antioxidants can be divided simply
into two: enzymatic and nonenzymatic (e.g. superoxide
dismutase and vitamin E, respectively) and further sub-
divided by other properties such as solubility. These
properties reflect the biological distribution of each anti-
oxidant and hence its likely potency in a given situation.
For example, vitamin E is profoundly lipophillic and
hence widely distributed throughout the phospholipid
bilayer. Antioxidants act to quench free radicals formed
by the result of incomplete reduction of oxygen. Free
radicals (including reactive oxygen intermediates, ROIs)
hold an odd number of electrons that can set in motion
a powerful chain of electron transfer reactions. This is the
manner in which free radicals cause their toxic effects.
As a result, a number of protective mechanisms exist to
quench such activity. The variety and quantity of these
defences reflect the relative damage unchecked reactions
can incur. Recent interest in transcription factors such as
nuclear factor-
 
k
 
B (NF-
 
k
 
B) has demonstrated that some
redox reactions can activate transcription factors leading
to up-regulated expression of various inflammatory
cytokines and cell adhesion molecules such as ICAM-1
[62]. Consequently, NF-
 
k
 
B blockade has been shown to
prevent vascular lesion formation in rats [63].
The link between elevated oxidative stress and endot-
helial dysfunction has been well documented in disease
states such as atherosclerosis, dyslipidaemia and type 2
diabetes, for review see Liplinski [64]. The increased
oxidative stress measurable in these conditions is thought
to reflect varying degrees of inflammation, lipoprotein
oxidation and nonenzymatic protein glycation [65].
The observation that increased vitamin E consumption
appears to be linked to a reduced incidence of cardio-
vascular events [66] has prompted a number of studies to
investigate the benefits of vitamin E supplementation.
Rather disappointingly, larger studies have failed to dem-
onstrate any significant reduction in 
 
cardiovascular mortal-
ity
 
. An exception is a Chinese study of almost 30 000
patients who were randomised to vitamin E, beta-
carotene and selenium or placebo [67]. This study found
a 9% decrease in all cause deaths over a 5.2 year follow
up. However, the underlying nutritional status of this
group is unlikely to match that of the general population
in the Western hemisphere and makes the relatively small
benefit even more disappointing. The HOPE study of
over 9000 high-risk patients failed to demonstrate any
significant difference in cardiovascular events between
those given vitamin E or placebo over the average
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4.5 year follow-up period [68]. Most recently, the Heart
Protection Study of 20 500 UK patients with diabetes or
vascular disease who were randomised to a vitamin com-
bination (vitamins E, C and beta-carotene) or placebo
failed to find significant differences in the incidence of
vascular/nonvascular death, nonfatal MI, stroke or cancer
despite measurable increases in plasma concentrations of
each vitamin over the 5 year study period [69]. The
discrepancy between earlier observational and more
recent randomised controlled trials is likely to be related
to the additional lifestyle differences (particularly dietary
consumption of additional antioxidant supplements) in
those groups observed to be at lower risk.
The relatively short follow-up period of many antiox-
idant studies has been thought to be a possible reason for
these negative results. However, 12-year follow-up of the
Physicians health study has shown no benefit in cardio-
vascular mortality [41]. Comparisons between patient
subgroups with, and without, evidence of cardiovascular
disease has also failed to show protective benefit [69]
countering arguments that antioxidants would be bene-
ficial in disease prevention rather than progression. Sim-
ilarly, subgroup analysis of diabetes patients, a group
known to have increased markers of oxidative stress, has
failed to show an effect [69]. Clinical trials on antioxidant
supplementation in nitrate tolerant cardiovascular patients is,
however, rather more encouraging. Randomised con-
trolled trials of ischaemic heart disease patients have
shown vitamin E (n = 48) and vitamin C (n = 48),
respectively, to have a protective effect on the develop-
ment of nitrate patch tolerance [70, 71]. Similar work
on vitamin C supplementation in 20 congestive cardiac
failure patients (New York Heart Association grades II-
IV) has also demonstrated prevention of an attenuated
haemodynamic effect during continuous intravenous
GTN administration [72]. Interestingly, this work also
revealed a significant reduction in measurable vitamin E
levels in the placebo treated group compared to the
vitamin C treated group. This suggests that antioxidants
work together to reduce oxidative stress so that one
antioxidant may regenerate another [72]. The rate of
reaction between nitric oxide and superoxide to produce
peroxynitrite is notoriously rapid [73]. Rate constants of
secondary antioxidants such as vitamins C and E are
much lower and this difference is probably overcome by
high concentrations of both vitamins.
Results of clinical trials on cardiovascular patients are
reflected in work on healthy volunteers: Bassenge et al.
demonstrated that following three days of transdermal
GTN administration with concurrent high dose vitamin
C, vascular tolerance could be ‘eliminated’ in 9 healthy
volunteers [74]. A wide variety of pharmacological
compounds exhibit antioxidant properties including
carvedilol a cardio-selective beta-blocker. A randomised
controlled trial of 40 heart failure patients treated with
either carvedilol, metoprolol, doxazosin or placebo
(n = 40) [75] has demonstrated that carvedilol, a beta-
blocker with antioxidant properties, also has protective
qualities against the development of nitrate tolerance. A
further randomised controlled study of 24 patients with
untreated hypertension confirmed the protective benefits
of carvedilol vs arotinolol (which does not display anti-
oxidant properties) or placebo [76]. It remains to be seen
whether the positive effects of antioxidant use obtained
in these trials concur with any future large-scale trials of
longer duration.
Conclusion
The evidence supports a free radical mechanism as a key
factor in the development of nitrate tolerance, which is
predominantly an endothelium dependant process. Spe-
cific therapy for this multifactorial phenomenon will,
however, probably rely on blocking a combination of
pathways [Figure 3], not least of which is the renin
angiotensin system [77]. Future work on elucidating
these mechanisms should enlighten clinical practice with
treatment strategies to reduce or even prevent nitrate
tolerance (for a mini review see References [78] and
[79]). The link between the nitric oxide pathway and
Figure 3 Potential therapy for nitrate tolerance.
ENOS, endothelial nitric oxide; ARBs, angiotensin receptor 
blockers; cGMP, cyclic guanosine mono-phosphate; PKC, Protein 
kinase C; BH4, tetrahydrobiopterin; GC, Guanylate Cyclase.
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endothelial dysfunction may provide profound insights
into the cornerstones of cardiovascular disease including
insulin resistance and atherosclerosis.
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